Abstract
To evaluate the safety and efficacy of L-glutamine in reducing vaso-occlusive crisis (VOC) and improving cerebral arterial blood flow in children with sickle cell disease (SCD). This is an interventional randomized controlled trial that recruited sixty SCD patients, aged 9.2 ± 3.7 years, who had at least two VOCs during the last 12 months and on a stable dose of hydroxyurea. They were randomly assigned in a 1:1 ratio to receive glutamine (0.3 gm/kg/dose/12h) orally for 24 weeks or the standard of care (SOC). All patients had VOCs in the last year > 3, those on glutamine had a higher number of VOCs and hospitalization for VOC in the last year. There was a decreasing trend in the number, severity, and hospitalization of VOC and a significantly lower cumulative number of VOCs and hospitalizations in the glutamine group than in SOC (p = 0.008, p < 0.001 respectively). Time-averaged mean maximum velocity for the glutamine group had a marginal increase in both middle cerebral arteries, all values remained normal within a normal range, and in both internal carotid arteries, values increased from abnormally low to normal ranges at week 24. Glutamine reduced the number of VOCs and severity and may have a potentially favorable impact on the cerebral arterial flow velocities.
Supplementary Information
The online version contains supplementary material available at 10.1007/s00277-024-05877-8.
Keywords: L-Glutamine, Sickle Cell Disease, Vaso-occlusive crisis, Children, Egypt
Introduction
Sickle cell disease (SCD) is one of the most common severe monogenic disorders rooted in a single base-pair point mutation of the hemoglobin β-chain resulting in an abnormal hemoglobin S (HbS) [1]. Patients with SCD suffer from unpredictable recurrent episodes of acute pain due to vaso-occlusive crisis (VOC) which may require hospitalization or from chronic persistent pain. This pain usually begins in infancy and continues throughout life, necessitating preventive rather than treatment measures [2].
The pathobiology of SCD is a vicious cycle of four major processes including HbS polymerization, impaired biorheology and increased adhesion-mediated vaso-occlusion, hemolysis-mediated endothelial dysfunction, and rigorous activation of sterile inflammation. These molecular and cellular processes synergize to promote both acute and chronic pain and result in end-organ injury and failure in SCD [3]. Although recurrent VOCs cause vital morbidity to those with SCD, however, morbidities can occur even in the absence of overt painful VOCs because of ongoing cumulative tissue injury [4]. Moreover, the unpredictable nature of this pain necessitates the use of opioids which is associated with several side effects, little is specific in the context of SCD, including hyperalgesia, tolerance, and addiction [5].
L-glutamine is an essential amino acid for the synthesis of the pyridines for nucleotides, including nicotinamide adenine dinucleotide (NAD) and glutathione, in addition to glutamate, especially during oxidative stress exposure. The sickle red blood cells (RBCs) had a lower NADH: [NAD+ + NADH] (redox) ratio than in normal RBCs which is related to oxidative stress, so the availability of L- glutamine is important in SCD [6]. In 2017, L-glutamine oral powder was approved by the U.S. Food and Drug Administration (FDA) to reduce SCD crisis episodes especially the VOCs. It can cause common non-serious adverse events like nausea, vomiting, stomach pain, gases, swelling in hands or feet, muscle or joint pain, back pain, headache, dizziness, tired feeling, mild skin rash or itching, dry mouth, runny nose, or increased sweating [7].
Our primary objectives were to assess the safety and efficacy of L-glutamine in patients with SCD in reducing the frequency of the occurrence of acute painful episodes from baseline to week 24 via calculating the percent change in the frequency of VOC. The secondary objectives were to determine the effect of L-glutamine on the percentage of change in transcranial Doppler (TCD)- time-averaged mean maximum velocity (TAMMV)- arterial cerebral blood flow, on the improvement of health-related quality of life (HRQOL) in patients with SCD from baseline to week 24, other exploratory objectives were to determine the changes in hematologic parameters and measures of hemolysis from baseline through week 24. The primary efficacy endpoint was the cumulative number of VOCs at 24 weeks, and the secondary endpoint was the change in TCD-TAMV in arterial cerebral blood flow at 24 weeks. The primary safety endpoint was the development of adverse events such as bleeding tendency, and significant impairment of liver or kidney functions.
Subjects and methods
This was a prospective phase IV interventional open-label randomized controlled investigator-initiated clinical trial. Using the PASS 15 program for sample size calculation, setting power at 80%, and alpha error at 5%, based on the result of a pilot study, we assumed an effect size difference equals 0.8 between the two groups regarding the mean frequency of the occurrence of the acute painful episode, based on this assumption a sample size of at least 30 patients per group was used. Consequently, sixty children and adolescents with SCD were recruited from the Hematology clinic at Ain Shams University Children’s Hospital during the period from the 4th of January 2022 through the 3rd of January 2023. The study was conducted after approval of the Ethical Committee of Ain Shams University Hospitals under acceptance number FMASU M D 199/ 2021 and was registered in clinicaltrials.gov, identifier number NCT05371184. An informed consent and assent were obtained from each patient and control (whenever applicable) and their legal guardians before enrolment in the study. All procedures were performed per the ethical standards of the institutional research committee under the Helsinki Declaration 2013.
Study population
Eligible participants were children and adolescents aged from five to eighteen years old, diagnosed with SCD by hemoglobin electrophoresis. Age eligibility was based on the FDA approval of l-glutamine oral powder in children aged 5 years and older [8]. They should have at least two documented VOCs with no upper limit during the previous year, where the VOC was defined as pain leading to treatment with a parenterally administered narcotic or non-steroidal anti-inflammatory in the emergency department (ED) or outpatient treatment centre or during hospitalization. For participants taking hydroxyurea (HU), the dose of HU (mg) per kg should be stable for at least 90 days before enrolment, and with no anticipated need for dose adjustments (other than weight-based). For participants not taking HU, there should be no anticipated need for initiation of HU in the opinion of the investigator. Diagnosis of SCD was made based on clinical picture, complete blood count (CBC), reticulocyte count, markers of hemolysis as well as hemoglobin analysis by high-performance liquid chromatography (HPLC) [9]. Patients with clinically significant renal, or liver disease (prothrombin-time international normalized ratio (INR) higher than 2.0, or serum albumin level of less than 3.0 g/dL), and those who received any blood products within 3 weeks before enrolment in the study were excluded.
Intervention
This is an investigator-initiated single-center prospective phase IV open-label interventional randomized controlled trial at Ain Shams Pediatric Hematology Unit. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Sixty participants were randomly assigned in a 1:1 ratio to receive glutamine for 24 weeks or the standard of care (SOC) without glutamine intake (Fig. 1). No placebo was used in this study owing to the technical difficulty of making a placebo of the same chemical and physical criteria at our institute consequently L glutamine was used as an add-on therapy to the SOC. The thirty patients in the interventional arm received l-glutamine as a powder that was mixed with water or any non-heated beverage or with any non-heated food such as yogurt, applesauce, or cereal immediately before ingestion orally twice a day [10], dosed based on body weight (0.3 g per kilogram per dose) and was adjusted in increments of 5 g up to a maximum of 15 g/dose with an upper limit of 30 g per day. Patients were given verbal instructions for self-administration of the study medication and written instructions were also included on the consent form. Patients were instructed that the study drug should be taken between 6 and 9 am and again between 6 and 9 pm. The main side effects of l-glutamine reported in the SCD clinical trials were constipation, nausea, headache, abdominal pain, cough, extremity pain, back pain, and chest pain [11].
Fig. 1.
Flow chart for patients’ disposition
Study tools
The detailed history
All patients were subjected to the detailed history through direct interviews of the subject and/or caregiver as well as collecting the data from the filling system including demographic characteristics, history of VOCs including the number of VOCs in the last year, its frequency per month, type and route of analgesics received at home and during hospitalization, hospitalization history, the severity of VOC, duration of admission in days, as well as the history of other complications, comorbidities, and operations. Detailed blood transfusion history (age of start transfusion, pre-transfusion Hb, simple and exchange transfusion, frequency per year and the complications as regards alloimmunization and infections), drug history including HU (age of start in years, maximum dose/kg/day, duration, compliance, and side effects), iron chelation (age of start in years, type, dose, duration, compliance, and side effects) was recorded.
Assessment of health-related quality of life (QoL)
HRQoL at the beginning and the end of the study using the Peds QL™ 3.0 SCD Module, Arabic version questionnaire for Children from 5–7, 8–12 years, Parents of children aged 5–7 and 8–12 years composed from 42 items comprising 9 dimensions. The questions included “feeling of pain, effects of pain, dealing with pain, feeling of anxiety, fearing, feeling of suffering from complications, feeling problems due to suffering sickle cell, problems of treatment and communications with others.” Their answers ranged from never a problem, problem sometimes, or problem many times [12].
Detailed physical examination
This includes weight in kg (standard deviation), height in cm (standard deviation), and body mass index (standard deviation). Growth stunting is identified by comparing measurements of children's heights and weight to the World Health Organization (WHO) 2006 growth reference population: children who fall below the fifth percentile of the reference population in height and weight for age are defined as stunted, regardless of the reason [1]. Sexual maturity rating using Tanner score [13] was assessed, where delayed puberty and hypogonadism were defined as an absence of sexual characteristics in girls till the age of 13 years and a testicular volume < 4 ml in boys till the age of 14 years [14], also detailed cardiac, chest, abdominal, and neurological examination were performed.
Laboratory
Baseline hemoglobin electrophoresis (HPLC) performed using D-10 (Bio-Rad, Marnes La Coquette, France) for initial Hb F levels, CBC with reticulocyte count using Sysmex XT-1800i (Sysmex, Kobe, Japan), markers of hemolysis in form of total serum and indirect bilirubin, alanine aminotransferase (ALT), aspartate transaminase (AST), and serum creatinine using Cobas Integra 800 (Roche Diagnostics, Mannheim, Germany) were performed before starting treatment with l-glutamine and on monthly bases through the 24 weeks, while serum ferritin level was measured at entry of the study on Immulite 1000 analyzer (Siemens Healthcare Diagnostics, Marburg, Germany).
Transcranial doppler (TCD)
TCD was performed for all participants (Figure S1) by a certified trained sonographer with the calculation of the TAMMV in the right and left MCA, right and left ACA, and right and left ICA at three-time points: before the start of treatment, after 12 weeks (three months) of glutamine, and at the end of the study in both study arms. The TAMMV was considered very low if less than 70 cm/s, normal if less than 170 cm/s, conditional if between 170 – 200 cm/s, and abnormal if above 200 cm/s [15].
Monthly clinic visits
Patients have been examined once monthly to answer questions designed to monitor compliance and adverse effects while the patient and/or parent completed a daily compliance diary, history of crises including the time to the first painful crisis after starting the L- glutamine and frequencies, severity with the need for hospitalization. A committee responsible for the justification of whether the event is considered VOC or not was formed by the investigators (Fatma Ebeid, Sara Mekkya, Nihal Hussien). QoL was assessed for all patients as well as their parents at the beginning and the end of the study, whereas TCD was evaluated for all participants at the beginning, after 12 weeks (after three months of treatment with glutamine), and at the end of the study.
Statistical methods
Demographic and clinical data will be obtained and recorded in a special registration form. Statistical data will be tabulated, and Statistical analysis is to be performed using Microsoft® Excel® version 2016 and SPSS® for Windows® version 27. Quantitative data will be presented as mean and standard deviation. An independent t-test will be used to compare the means of the two groups. Qualitative data will be presented as numbers and percentages. The chi-square test or Fisher exact test will be used to compare between two or more proportions. The two groups were compared first as regards the presence or absence of VOCs using the Chi-Square test, then the cumulative number of VOCs by the Mann–Whitney test. Univariate Odds ratio/Risk ratio will be calculated for each studied risk factor. The significance level was set at 0.05.
Results
Sixty participants were recruited, their mean age was 9.2 ± 3.7 years, and they were 35 males and 25 females. Thirty SCD patients were recruited in each group either received glutamine or SOC, both groups were comparable as regards demographic data (Table 1). All patients in both arms had VOCs in the last year more than three, however patients on glutamine had a higher number of VOCs (P < 0.001) and hospitalization (P = 0.006) for VOC in the last year, but the VOC severity was comparable between the two groups at baseline (Table 2), in addition, they had higher hospitalization frequency for causes other than VOC. SCD complications illustrated in Table 1, all recruited participants had a history of hemolytic crisis, while. none of the patients in either group had a history of hepatic sequestration, intrahepatic cholestasis, HBV infection, manifest renal or cardiac complication, or leg ulcer.
Table 1.
Comparison between the two studied groups regarding their demographic and disease characteristics
| Glutamine arm (Intervention group) n = 30 |
Standard of care arm (Control group) n = 30 |
P-value | ||
|---|---|---|---|---|
| Gender; n (%) | Females | 15.0 (50.0) | 10.0 (33.3) | 0.190 |
| Males | 15.0 (50.0) | 20.0 (66.7) | ||
| Age (Year); Mean ± SD | 9.1 ± 3.5 | 9.4 ± 3.9 | 0.690 | |
| Positive Consanguinity; n (%) | 14.0 (46.7) | 15.0 (50.0) | 0.796 | |
| Positive family history of SCD; n (%) | 18.0 (60.0) | 20.0 (66.7) | 0.592 | |
| Age of diagnosis in months; Mean ± SD | 20.2 ± 27.4 | 26.7 ± 22.6 | 0.316 | |
| Disease Duration (Years); Median (IQR) | 7.0 (5.0—8.5) | 6.3 (5.0—10.4) | 0.739 | |
| Hb electrophoresis | HbA%; Median (IQR) | 9.9 (0.0 – 22.0) | 8.6 (0.0 – 20.0) | 0.485 |
| HbA2%; Median (IQR) | 3.0 (2.4—3.8) | 3.2(2.7 – 4.0) | 0.336 | |
| HbF%; Median (IQR) | 14.5 (10.1 – 24.0) | 11.9 (8.3—17.3) | 0.261 | |
| HbS%; Median (IQR) | 63.5 (60.0—73.5) | 72.0 (62.5—77.2) | 0.108 | |
| Type of sickle; n (%) | SB0% | 3.0 (10.0) | 1.0 (3.3) | 0.285 |
| SS% | 19.0 (63.0) | 18.0 (60.0) | ||
| SB + % | 6.0 (20.0) | 10.0 (33.3) | ||
| SC% | 0.0(0.0) | 1.0 (3.3) | ||
| SO arab% | 2.0 (6.7) | 0.0 (0.0) | ||
| Comorbidities | Sequestration crisis; n (%) | 1 (3.3) | 2 (6.7) | 0.554 |
| Aplastic crisis; n (%) | 5 (16.7) | 0.0 | NA | |
| Acute chest syndrome; n (%) | 11 (36.7) | 4 (13.3) | 0.037 | |
| Manifest Stroke; n (%) | 0(0.0) | 1 (3.3) | 0.313 | |
| Avascular necrosis of hip; n (%) | 1 (3.3) | 1 (3.3) | 1.000 | |
| Cholecystitis; n (%) | 4 (13.3) | 4 (13.3) | 1.000 | |
| Cholelithiasis; n (%) | 4 (13.3) | 1 (3.3) | 0.161 | |
| Splenectomy; n (%) | 5 (16.7) | 5 (16.7) | 1.000 | |
| Cholecystectomy; n (%) | 4 (13.3) | 5 (17.2) | 0.676 | |
| Others; n (%) | 5(16.7)* | 3 (10)# | 0.448 | |
| Frequency of hospital admission for causes other than vaso occlusive crisis (VOC) /year; Median (IQR) | 4 (2—6) | 0 (0—2) | 0.000 | |
| Duration of hospital admission for causes other than VOC/year (day); Median (IQR) | 12 (6—20) | 10 (5—15) | 0.627 | |
| Hydroxyurea | Age of start (years); Median (IQR) | 2 (2—2) | 2 (1—4) | 0.810 |
| Duration (year); Median (IQR) | 6 (4—9) | 6.5 (3—8) | 0.705 | |
| Blood Transfusion | Age at first transfusion (year); Median (IQR) | 1 (0.7—2) | 2.5 (1—4.5) | 0.005 |
| Pre transfusion HB mg\dl; Mean ± SD | 6.2 ± 0.8 | 6.5 ± 1.1 | 0.158 | |
| Simple transfusion frequency/year; Median (IQR) | 6.5 (3—12) | 4.5 (2—6) | 0.008 | |
| Exchange transfusion; n (%) | 9(30) | 5 (16.7) | 0.222 | |
| Iron Chelation | Deferasirox | 15 (50) | 14 (46.7) | 0.796 |
| Dose mg/kg/day; Mean ± SD (Range) | 19.4 ± 4.15 (14 – 28) | 22.57 ± 2.65 (20 – 28) | 0.022 | |
| Age at start in year; Mean ± SD (Range) | 3.27 ± 1.67 (2 – 6) | 2.71 ± 1.86 (2 – 8) | 0.406 | |
| Pain killer; n (%) | Duration in year; Mean ± SD | 5.8 ± 2.54 | 7.21 ± 3.72 | 0.240 |
| Paracetamol | 11 (36.7) | 8 (26.7) | 0.001 | |
| Non- steroidal anti inflammatory | 13 (43.3) | 3 (10.0) | ||
| Both | 6 (20) | 19 (63.3) | ||
| Pain killer frequency; n (%) | On demand | 22 (73.3) | 30 (100) | 0.002 |
| Regular | 8 (26.7) | 0 (0.0) | ||
Other complications in glutamine arm* included portal vein thrombosis, splenic infarction, osteomyelitis, and two performed surgeries for tendon release and tonsillectomy and adenoidectomy. While in control group# one patient had hypoparathyroidism and hypothyroidism, and the other patient had G6PD deficiency
Table 2.
Comparison between the two studied groups regarding vaso-occlusion crisis parameters of the studied patients through the six months of study period
| Glutamine arm (intervention group) n = 30 |
Standard of care arm (Control group) n = 30 |
P-value | ||
|---|---|---|---|---|
| Baseline | ||||
| Number of vaso -occlusion crisis Last year; Median (IQR)(Range) | 12.0 (7.0 – 20.0) (6.0 – 25.0) | 7.0 (6.0 -10.0) (4.0 – 20.0) | < 0.001 | |
| Mean Duration of Vaso-occlusion(days); Mean ± SD (Range) | 3.3 ± 1.2 (2.0 – 5.0) | 3.7 ± 1.7 (2.0 – 10.0) | 0.302 | |
| Severity of vaso ooclusion crisis; n (%) | Non-severe | 18.0 (60.0) | 11.0 (36.7) | 0.071 |
| Severe | 12.0 (40.0) | 19.0 (63.3) | ||
| Laboratory data | ||||
| Hemoglobin (g\dl); Mean ± SD (Range) | 8.7 ± 1.5 (6.8—12.4) | 8.7 ± 1.7 (6 – 13) | 0.937 | |
| White blood cells (103/UL); Median (IQR)(range) | 8.5 (7.2—13.9) (4.2—27.6) | 9.1 (6.3—13.9) (4.5 – 21) | 0.802 | |
| Platelet(103/UL); Median (IQR) (Range) | 315.5 (226—395) (73 – 1076) | 312.5 (240—501) (108 – 815) | 0.802 | |
| Retics (%); Median (IQR) (Range) | 4 (2.5—6.5) (2 – 14) | 3 (2.2—4) (0.5—13.7) | 0.068 | |
| Serum ferritin(ng/ml); Median (IQR) (Range) | 557.5 (311—1538) (100 – 3756) | 665 (260—2139) (100– 5000) | 0.535 | |
| Total bilirubin (mg/dl); Mean ± SD (Range) | 2..2 ± 1.1 (0.5—4.2) | 2.3 ± 1.1 (0.6 – 5) | 0.591 | |
| Direct bilirubin(mg/dl); Mean ± SD (Range) | 0.4 ± 0.2 (0.1—0.9) | 0.37 ± 0.21 (0.1—0.8) | 0.779 | |
| Alanine aminotransferase (U/L); Median (IQR) (Range) | 23.0 (19—30) (14 – 76) | 23.4 (20—32) 16.7 – 81 | 0.515 | |
| Aspartae aminotransferase (U/L); Median (IQR) (Range) | 37.4(28—45) (13 – 100) | 44.5 (34—56) (22.4 – 103) | 0.042 | |
| Urea(mg/dl); Mean ± SD (Range) | 21.1 ± 5.7 (8—32.3) | 19 ± 5.3 (11.7 – 33) | 0.140 | |
| Creatinine(mg/dl); Mean ± SD (Range) | 0.5 ± 0.2 (0.2—0.8) | 0.4 ± 0.1 (0.2—0.6) | 0.354 | |
| Sixth month of start of glutamine | ||||
| Vaso-occlusion crisis; n (%) | 2 (6.7) | 9 (30.0) | 0.02 | |
| Number/ month; Median (IQR) (Range) | 1 (1—1) (1 – 1) | 1 (1—1) (1 – 1) | 1 | |
| Mean duration(days); Mean ± SD (Range) | 1 ± 0 (1 – 1) | 2.6 ± 0.5(2 – 3) | 0.001 | |
| Severity; n (%) | Non-severe | 2 (100.0) | 7 (77.8) | 0.118 |
| Severe | 0 (0.0) | 2 (22.2) | ||
| Hospitalization for vaso-ooclusion crisis; n (%) | 0 (0.0) | 4 (44.4) | 0.461 | |
| Laboratory data | ||||
| Hemoglobin(g\dl); Mean ± SD (Range) | 8.5 ± 0.7 (7—10.6) | 9.01 ± 1.4 (6.9—12.8) | 0.080 | |
| Platelet(103/UL); Median (IQR) (Range) | 280.5 (250—330) (95 – 880) | 295 (248—350) (190 – 889) | 0.344 | |
| White blood cells (103/UL); Median (IQR) (Range) | 7.9 (6.6—9) (4.5 – 78) | 8.6 (7.2—16) (5.8—22.4) | 0.203 | |
| Retics (%); Median (IQR) (Range) | 2.7 (2.2—3.4) (0.8 – 26) | 3.05 (2.2—4) (0.5 – 5) | 0.124 | |
| Aspartae aminotransferase(U/L); Median (IQR) (Range) | 30 (25—32) (19 – 39) | 29.5 (19—44) (13 – 86) | 0.870 | |
| Alanine aminotransferase (U/L); Median (IQR) (Range) | 27 (24—30) (12 – 34) | 20 (19—22.5) (14 – 29) | < 0.001 | |
| Total bilirubin(mg/dl); Mean ± SD (Range) | 2.92 ± 4.22 (0.8 – 25) | 2.94 ± 0.51 (2.2—3.8) | 0.976 | |
| Urea (mg/dl); Mean ± SD (Range) | 21.17 ± 2.15 (18 – 29) | 32.3 ± 37.3(21 – 229) | 0.108 | |
| Creatinine (mg/dl); Mean ± SD (Range) | 0.4 ± 0.1 (0.3—0.6) | 0.3 ± 0.1 (0.2—0.6) | 0.002 | |
Physical examination of patients revealed 13 (43.3%) in the glutamine arm and 14(63.3%) in the standard of care arm had hepatosplenomegaly, their median Tanner score (IQR) 1 (1–1) and 1 (1–2) for glutamine arm, the standard of care arm respectively (P = 0.007). Their weight SDS and BMI SDS were significantly lower glutamine arm (p = 0.001, 0.002) than in SOC.
All recruited children who received HU were compliant and on stable doses except at week 12, two patients in the glutamine arm had an increase in dose as they developed hemolytic anemia and one patient in SOC had an increase in dose of HU due to the severity of VOC during hospitalization. All patients received prophylactic folic acid to prevent megaloblastic anemia and cardio-protective l-carnitine as SOC.
All patients received a blood transfusion at a certain time point in their lives; those on glutamine started transfusion at a younger age, as regard complications one patient in each group had a HVC infection, and alloimmunization was reported in three patients in the glutamine arm, and two in SOC arm. Through the study, seven patients on glutamine received simple transfusion due to a drop in hemoglobin level, and three patients needed exchange, one of them had a history of splenic infarction, and the other two had exchange transfusion due to severe VOC in the previous year while fifteen patients in the SOC arm received simple transfusion due to drop of hemoglobin and four patients required exchange transfusion, due to severe VOC in the previous year. Fifteen patients on glutamine received iron chelation (deferasirox) all were compliant except one patient who developed thrombocytopenia. Fourteen patients on SOC received deferasirox and had no adverse effects except one patient who had elevated liver enzymes.
As regards the efficacy endpoint, at baseline, there was a higher number of VOC and hospitalizations due to VOC in the last year in glutamine than those in the SOC arm. On the follow-up (Table 2) there was a decrease in the number, severity, and hospitalization of VOC in the glutamine arm and there was a significantly lower cumulative number of VOCs in the glutamine group than SOC, the mean of the percent of change in the frequency of VOC was 83.33 ± 36.44 and lower cumulative number of hospitalizations (p < 0.001). As regards the hemoglobin and markers of hemolysis, there was no difference between the two groups except at week 12, the reticulocyte count was higher in those on SOC (P = 0.000).
As regards TCD parameters at baseline and at follow-up in the glutamine arm, illustrated in Table 3 and Figure S2, showed that there were four patients in the glutamine arm below 70cm/sec in the left MCA at baseline, dropped to three patients at week 12 and none at week 24, while no significant changes were recorded in the reading of TCD all through the time during the study period in SOC. Regarding the quality of life, patients in glutamine arm had significant improvement in pain, how to deal with pain, anxiety, anger, and treatment problems for children and parents of children aged 5–7 years and age 8–12 years as illustrated in Fig. 2 and 3 as well as Table 4 and S1.
Table 3.
Comparison between the two studied groups regarding Transcranial Doppler parameters at baseline, after three months and after six months of follow up
| TCD parameter | Base line | P-value | After three months | P-value | After six months | P- value | |||
|---|---|---|---|---|---|---|---|---|---|
| Glutamine arm | Standard of care arm | Glutamine arm | Standard of care arm | Glutamine arm | Standard of care arm | ||||
| Rt Middle cerebral artery (cm/sec); Mean ± SD (Range) | 113.9 ± 18.8 (80 – 150) | 108.2 ± 27.1 (43 – 163) | 0.520 | 113 .0 ± 17.8 (82 – 161) | 117.3 ± 21.7 (72 – 150) | 0.406 | 117.7 ± 13. 5(90 – 159) | 117.3 ± 21.7 (72 – 150) | 0.932 |
| Lt Middle cerebral artery (cm/sec); Mean ± SD (Range) | 108.2 ± 27.1 (43 – 163) | 122.7 ± 25.8 (75 – 179) | 0.038 | 110.7 ± 24.3 (65 – 159) | 122.7 ± 25.0 (75 – 179) | 0.069 | 116.1 ± 17.6(70 – 155) | 122.7 ± 25.7 (75 –179) | 0.252 |
| RT anterior cerebral artery (cm/sec); Mean ± SD (Range) | 106.7 ± 23.9 (40 – 156) | 101.8 ± 24.2 (59 – 160) | 0.437 | 109.1 ± 22.4 (57 – 158) | 101.8 ± 24.2 (59 – 160) | 0.237 | 111.2 ± 15.9 (60 – 145) | 101.8 ± 24.2 (59 – 160) | 0.082 |
| LT anterior cerebral artery (cm/sec); Mean ± SD (Range) | 111.5 ± 13.2 (89 – 145) | 105.2 ± 24.5 (58 – 154) | 0.214 | 109.3 ± 15.3 (78 – 133) | 105.2 ± 50 (58 – 154) | 0.438 | 113.7 ± 13.1(90 – 130) | 105.2 ± 24.3 (58 – 154) | 0.098 |
| RT internal carotid artery (cm/sec); Mean ± SD (Range) | 64.5 ± 21.2 (26 – 95) | 54.2 ± 20.8 (31 – 106) | 0.062 | 66.7 ± 18.5 (30 – 97) | 53.7 ± 20.9 (31 – 106) | 0.014 | 72.4 ± 15.6 (38 – 90) | 53.4 ± 20.5 (31 – 106) | < 0.001 |
| LT internal carotid artery (cm/sec); Mean ± SD (Range) | 64.2 ± 18.5 (30 – 105) | 5 7.4 ± 22.0 (25 – 114) | 0.202 | 67.0 ± 15.7 (28 – 103) | 58.9 ± 22.5 (25 – 114) | 0.113 | 72.5 ± 13.4(30 – 95) | 58.1 ± 21.8 (25 – 114) | 0.003 |
Fig. 2.
Total score of children and parents aged 5—7 years and 8–12 years at follow-up after six months of treatment of glutamine
Fig. 3.
Correlation between children's total score with disease duration (years) and mean duration of VOC (days) (Above) and between parents' total score with disease duration (years) and mean duration of VOC (days)
Table 4.
Comparison between the two studied groups regarding PedsQl (Acute version 3.0 Arabic Egypt) at baseline and follow up after six months
| PedsQL (Acute Version 3.0 Arabic Egypt) Mean ± SD |
Baseline | P-value | follow up after six months | P-value | Baseline/follow up | |||
|---|---|---|---|---|---|---|---|---|
| Intervention group n = 30 |
Control group n = 30 |
Intervention group n = 30 |
Control group n = 30 |
Intervention group P-value |
Control group P-value |
|||
| Children aged 5—7 years | ||||||||
| My pain | 60.4 ± 11.4 | 54.9 ± 11.6 | 0.243 | 77.4 ± 5.5 | 54.9 ± 11.6 | < 0.001 | < 0.001 | 1.000 |
| Effects of pain | 49.3 ± 18.8 | 53.4 ± 12.4 | 0.513 | 71.3 ± 13.4 | 53.4 ± 12.4 | 0.002 | 0.003 | 1.000 |
| How to deal with your pain | 56.7 ± 20.6 | 54.9 ± 12.2 | 0.719 | 75 ± 15.1 | 54.3 ± 12.3 | < 0.001 | 0.020 | 1.000 |
| Anxiety problems with pain | 48.6 ± 17.5 | 56.5 ± 6.2 | 0.132 | 63.4 ± 11.6 | 56.6 ± 6.8 | 0.077 | 0.030 | 1.000 |
| Angry feeling | 38.3 ± 18.0 | 45.7 ± 18.3 | 0.312 | 63.4 ± 11.5 | 45.7 ± 18.3 | 0.008 | < 0.001 | 1.000 |
| Treatment problems | 66.9 ± 12.6 | 64.5 ± 9.2 | 0.577 | 76.2 ± 11.8 | 64.5 ± 9.2 | 0.011 | 0.091 | 1.000 |
| Communications problems | 61.7 ± 17.1 | 58.1 ± 11.5 | 0.533 | 63.3 ± 8.3 | 59.1 ± 12.2 | 0.314 | 0.755 | 0.336 |
| Total score | 54.5 ± 10.2 | 55.3 ± 5.7 | 0.805 | 69.9 ± 7.7 | 55.5 ± 5.8 | < 0.001 | < 0.001 | 0.336 |
| Parents of children | ||||||||
| Feeling of pain | 55.2 ± 12.5 | 55.2 ± 7.3 | 0.989 | 82.2 ± 6.2 | 55.2 ± 7.2 | < 0.001 | < 0.001 | 1.000 |
| Effects of pain | 45.2 ± 16.3 | 54.7 ± 11.6 | 0.095 | 73.6 ± 8.8 | 54.7 ± 11.6 | < 0.001 | < 0.001 | 1.000 |
| Dealing with pain | 44.2 ± 11.6 | 61.4 ± 5.3 | 0.000 | 73.3 ± 17.7 | 60 ± 0.0 | 0.009 | < 0.001 | 0.336 |
| Feeling of anxiety, fearing | 40 .0 ± 9.2 | 40.6 ± 18.2 | 0.923 | 72 ± 13.8 | 40.5 ± 18.2 | < 0.001 | < 0.001 | 1.000 |
| Feeling of suffering from complications | 40.8 ± 12.4 | 37.14 ± 18.99 | 0.57 | 60 ± 0 | 37.1 ± 18.9 | < 0.001 | < 0.001 | 1.000 |
| Feeling Problems due to suffering sickle cell | 38.3 ± 11.2 | 37.1 ± 18.9 | 0.85 | 56.6 ± 7.7 | 37.1 ± 18.9 | 0.003 | < 0.001 | 1.000 |
| Problems of treatment | 60.8 ± 17.5 | 59.1 ± 17.9 | 0.8 | 60.8 ± 2.8 | 59.1 ± 17.9 | 0.736 | 1.000 | 1.000 |
| Communications with others | 56.1 ± 10.8 | 58.1 ± 11.5 | 0.656 | 60 ± 0.0 | 58.1 ± 11.5 | 0.573 | 0.238 | 1.000 |
| Total score | 47.5 ± 6.5 | 50.4 ± 5.9 | 0.255 | 67.3 ± 4.2 | 50.2 ± 5.9 | < 0.001 | < 0.001 | 0.336 |
| Children aged 8—12 years | ||||||||
| My pain | 41.1 ± 12.6 | 39.4 ± 11.8 | 0.695 | 78.7 ± 2.8 | 39.5 ± 11.8 | < 0.001 | < 0.001 | 0.333 |
| Effects of pain | 28.6 ± 12.8 | 45.75 ± 12.22 | 0.000 | 62.2 ± 6.2 | 45.4 ± 12.5 | < 0.001 | < 0.001 | 0.333 |
| How to deal with your pain | 40.0 ± 19.4 | 43.7 ± 18.2 | 0.567 | 72.2 ± 15.5 | 46.25 ± 17.4 | < 0.001 | < 0.001 | 0.333 |
| Anxiety problems with pain | 29.3 ± 16.3 | 36.5 ± 15.8 | 0.204 | 63.5 ± 7.3 | 36.7 ± 15.8 | < 0.001 | < 0.001 | 0.333 |
| Angry feeling | 38.8 ± 14.5 | 38.75 ± 17.08 | 0.98 | 76.6 ± 10.3 | 41.5 ± 19.9 | < 0.001 | < 0.001 | 0.333 |
| Treatment problems | 48.3 ± 17.5 | 52.3 ± 19.6 | 0.54 | 69.2 ± 5.6 | 57.3 ± 21.1 | 0.027 | < 0.001 | 0.333 |
| Communications problems | 52.6 ± 14.8 | 52.9 ± 16.4 | 0.952 | 68.9 ± 15.2 | 57.9 ± 17.8 | 0.061 | 0.003 | 0.333 |
| Total score | 39.8 ± 10.9) | 44.2 ± 6.9 | 0.182 | 70.2 ± 6.4 | 46.3 ± 8.4 | < 0.001 | < 0.001 | 0.336 |
| Parents of children | ||||||||
| Feeling of pain | 36.9 ± 14.9 | 47.4 ± 11.1 | 0.028 | 70.9 ± 4.9 | 47.4 ± 11.1 | < 0.001 | < 0.001 | 1.000 |
| Effects of pain | 32.56 ± 10.1 | 48.25 ± 14.93 | 0.001 | 68.6 ± 6.5 | 48.3 ± 14.9 | < 0.001 | < 0.001 | 1.000 |
| Dealing with pain | 36.11 ± 9.16 | 45.62 ± 17.11 | 0.048 | 63.3 ± 8.4 | 45.6 ± 17.1 | < 0.001 | < 0.001 | 1.000 |
| Feeling of anxiety, fearing | 34.2 ± 8.9 | 47.7 ± 14.1 | 0.002 | 66.6 ± 10.9 | 47.75 ± 14.1 | < 0.001 | < 0.001 | 1.000 |
| Feeling of suffering from complications | 32.7 ± 9.5 | 40 ± 16.3 | 0.121 | 62.7 ± 13.6 | 40 ± 16.3 | < 0.001 | < 0.001 | 1.000 |
| Feeling Problems due to suffering sickle cell | 32.7 ± 9.5 | 38.7 ± 17.08 | 0.211 | 61.1 ± 8.3 | 38.7 ± 17.1 | < 0.001 | < 0.001 | 1.000 |
| Problems of treatment | 41.1 ± 10.5 | 53.5 ± 13.2 | 0.005 | 63.7 ± 8.6 | 53.5 ± 13.3 | 0.012 | < 0.001 | 1.000 |
| Communications with others | 39.6 ± 14.4 | 55.0 ± 11.5 | 0.002 | 62.2 ± 6.4 | 55 ± 11.5 | 0.029 | < 0.001 | 1.000 |
| Total score | 35.7 ± 7.1 | 47.1 ± 10.4 | 0.001 | 64.9 ± 5.6 | 47.1 ± 10.4 | < 0.001 | < 0.001 | 1.000 |
| Total children score) | 39.8 ± 10.9 | 44.2 ± 6.9 | 0.194 | 70.2 ± 6.3 | 46.3 ± 8.3 | < 0.001 | < 0.001 | 0.300 |
| Total parents score | 35.7 ± 7.1 | 47.1 ± 10.4 | 0.001 | 64.9 ± 5.6 | 47.1 ± 10.4 | < 0.001 | < 0.001 | 0.326 |
As regards safety, five patients developed nausea, mild abdominal pain, and loose stool starting at week four of l-glutamine, and another four patients developed nausea, mild abdominal pain, a loose stool at week 12, and all resolved spontaneously. One serious adverse event (SAE) was reported, one patient after 12 weeks of treatment with l glutamine, presented with disturbed consciousness level, fever, vomiting, right upper quadrant abdominal pain, darkening of his urine with a deepening of his jaundice, and tachypnea, elevated transaminases tenfold with direct hyperbilirubinemia, derangement of kidney functions with abnormal bleeding profile, and metabolic acidosis with a positive anion gap, patient was diagnosed as sickle cell hepatopathy (SCH), admitted to PICU and was managed with supportive measures together, with exchange transfusion. The patient’s general condition improved with regaining full consciousness level and improvement of his labs and was planned for regular exchange transfusion, he stopped l-glutamine and was withdrawn from the study. As regards compliance, all patients were compliant and needed no change of dose of glutamine and only one patient withdrew from the study due to SAE. The ALT was significantly higher in the glutamine arm (p = 0.000) at week 12, this is due to the patient who developed SCH and was statistically significantly higher at week 24 (p < 0.001) but non-clinically significant as all values were within normal range. The serum creatinine was statistically significantly higher at week 24 (p = 0.002) but non-clinically significant as all values were within the normal range (Table 2 and Fig. 4).
Fig. 4.
relation between alanine aminotransferase (above) and aspartame aminotransferase (below) of sixty patients through the six months of follow-up
A correlation study regarding questionnaire results of children and their parents at baseline in the glutamine arm (Table S1) showed that the age at diagnosis was positively correlated with how the child dealt with pain (p = 0.047), and feeling anger (p = 0.018), and disease duration was negatively correlated with most of the items of the assessment. The number of VOCs in last year correlated negatively with parental feelings of anxiety, fear (p = 0.024), feeling of suffering from complications (p = 0.003), feeling problems due to suffering sickle cell (p = 0.009), while the mean duration of VOC correlated negatively with child pain (p = 0.002), effects of pain (p = 0.002), how to deal with your pain (p = 0.022), anxiety problems with pain (p = 0.028), parental effects of pain (p = 0.035), feeling of anxiety, fearing (p = 0.010), feeling of suffering from complications (p = 0.008), feeling problems due to suffering sickle cell (p = 0.015), parents total score (p = 0.011). Correlation study regarding questionnaire results of children and their parents at baseline in SOC group illustrated in Table S2.
Discussion
Over the last 50 years, there have been great improvements in the management of SCD. Until 2017, treatment options for SCD largely consisted of RBC transfusion [16], iron chelation [17], and HU [18, 19]. The story of l-glutamine as a proposed treatment for SCA started years ago, remarkably in the 1970s when there was a great interest in finding nontoxic “antisickling” agents [20]. In the 1980s, the finding that there is a decreased ratio of reduced NAD to total NAD in sickle RBCs compared with normal ones was discovered [21], and in the 1990s with the breakthrough discovery that there is a marked increased glutamine transport into sickle RBCs and ongoing oxidative injury support increased NAD synthesis and decreased NAD redox potential [22].
The l-glutamine, the second drug used to reduce acute complications of SCD, was approved by the FDA in 2017 for use in patients over age 5 based on a phase 3 trial [7] The study by Niihara et al., recruited 230 patients from participating sites across the United States only and children aged from five to 12 years old representing only 22.4% [7], our study design to assess the safety and efficacy of L-glutamine in patients with SCD in a younger age group who all of them below 18 and in the different ethnic background to ensure the diversity of the result.
As 95% of patients with SCD get hospitalized due to severe episodes of pain or VOCs [23] and alleviating VOCs reduces both the frequency and duration of hospitalizations [24], our study aims to assess the effect of l-glutamine on in reducing the frequency of VOCs. In addition, our study evaluated the percentage of change in TCD- TAMMV- arterial cerebral blood flow, and its effect on improving HRQOL.
L-glutamine is a conditionally essential amino acid in SCD due to the high RBC turnover [25], and its therapeutic mechanism is mainly through its antioxidant effects [7]. Glutamine suppresses several inflammatory signaling pathways, including suppressing nuclear factor-κB (NFκB) signaling pathway [26] and signal transducer and activator of transcription (STAT) pathways [27], by increasing the expression of cellular HSPs such as HSP25 and HSP70 [28] and inhibition of the expression of IL-8 which activates and stimulates the migration of neutrophils to inflammatory sites [29].
In our study, sixty participants were recruited; their mean age was around nine years old, and all of them were on HU stable dose at enrollment, as long-term use of HU is safe and well-tolerated in large cohorts of children and adults with SCD, reducing mortality and morbidity of both children and adult patients [30, 31].
At baseline, all patients in both arms have had VOCs in the last year more than three; patients on glutamine had a higher number of VOCs and hospitalization for VOCs in the last year. However, after the start of one month of the glutamine, there was a significant improvement in the severity of VOCs and number of hospitalizations for VOCs, this improvement continues through the treatment period. After 24 weeks of treatment with glutamine, there was a significant decrease in the number and severity of VOCs and hospitalization of VOCs in the glutamine arm.
Several studies prove the effect of l-glutamine on reducing the frequency of VOCs; a randomized controlled trial recruited 81 SCD patients aged from 9 to 58 years, who were randomized 1:1 to glutamine 0.3 g/kg orally twice daily or placebo for 48 weeks showed that l-glutamine therapy reduced the frequency of hospitalization and indicated a positive trend towards reducing the frequency of painful crises [10], also results of a phase 3 trial showed that treatment with l-glutamine led to a statistically significant reduction in the frequency of pain crises and rates of hospitalization [7], Elenga and his colleagues reported that SCD patients, whom nearly half of them receiving HU simultaneously (47%), demonstrated a clinically significant reduction in the median frequency of VOCs at 24-, 48- and 72-weeks following L-glutamine therapy compared to the preceding year [32].
In our study, after 24 weeks of treatment, L-glutamine did not cause a reduction in hemolysis markers nor improvement of hemoglobin level, as there was no difference between the two groups except at week 12, the reticulocyte count was higher in those on SOC. This is in agreement with a phase 3 study [7] in that neither the Hb nor the reticulocyte counts differed significantly between the group assigned to L-glutamine and placebo. Cox et al. reported there is no evidence currently that hemoglobin increases on l-glutamine or that hemolysis is reduced [6]. On the other side for the first time, Elenga et al. demonstrated significant improvement in clinical parameters along with improvement in hemolysis parameters as regards reticulocyte count, LDH, Hemoglobin level, and hematocrit level [32].
In children, cerebral vasculopathy is the most common CNS complication resulting from progressive inflammation and oxidative endothelial damage within intracranial vessels, with the influence of some genetic modifiers [33], leading to increased risk of transient ischemic events and infarcted strokes [34] and long term neurocognitive and psychiatric problems [35]. Screening for vasculopathy beginning at age two is recommended [36] in the form of TCD measurements which are effective in identifying children with SCA at the highest risk for stroke [37]. In our cohort, TCD parameters at baseline and follow-up in the glutamine arm, there were four patients in the glutamine arm below 70cm/sec in the left MCA at baseline, dropped to three patients at week 12 and none at week 24. Although l-glutamate is the most abundant amino acid in the brain and a key neurotransmitter involved in the maintenance of brain health and plasticity [38] under chronic oxidative stress, levels of deoxygenated hemoglobin in the brain may increase with increasing GSH depletion, affecting brain microstructure and cognitive function [39], no published study addresses the effect of L-glutamine on TCD measurements.
The glutamine role in the quality of life or other patient-reported outcomes needs to be examined and should not be overlooked [40] we reported that in patients who received glutamine, there was a significant improvement in pain, how they dealt with pain, anxiety, anger and treatment problems for children and parents of children aged 5–7 years and age 8–12 years.
Most of the adverse events in our cohort were nausea, mild abdominal pain, and loose stool which resolved spontaneously, this is in agreement with the previous study [7]. Glutamine is an important substrate for rapidly dividing cells, for instance, RBCs, which is a major site of glutamine consumption [41]. Intestinal pathophysiologic changes that may be modified by glutamine in SCD include increased intestinal permeability and increased translocation of bacteria into the systemic circulation promoting ongoing inflammatory processes that activate blood cells and platelets involved in the development of VOC. Glutamine may have a role in improving intestinal health, fortifying intestinal barrier functions, modifying microbial compositions, and decreasing inflammatory processes [42]. Glutamine may modify the intestinal microbial community [43], it reduces the abundance of Clostridium spp. in the ileum and Helicobacter spp. in the ileum and cecum [44] this may be related to nitrogen balance and protein synthesis by the Firmicutes spp. residing in the small intestine [45].
One SAE reported after 12 weeks of treatment with l glutamine as sickle cell hepatopathy (SCH) completely recovered and withdrawn from the study. At the end of the study, ALT and serum creatinine were statistically significantly higher but non-clinically significant as all values were within the normal range. There is no long-term data about glutamine use in SCD who are at risk of renal insufficiency, hepatic dysfunction, and multiorgan failure, all conditions associated with increased mortality in other trials of l-glutamine [20].
Challenges of usage of glutamine, it is much more expensive and naturalistic, so it is reasonable to consider its usage only after the optimization of HU therapy and not at the risk of reducing adherence to HU and use it as a primary therapy for those who tolerate HU poorly [20].
Conclusion
L-glutamine appears to be reasonably well tolerated in the short term, and effectively reduced the number of VOCs and hospitalizations for VOC and might have a potential favorable impact on the cerebral arterial flow velocities. However, larger long-term studies are needed.
Supplementary Information
Below is the link to the electronic supplementary material.
Author contributions
Fatma Soliman Elsayed Ebeid design and supervise the study, drafted the first and submitted manuscript.
Nihal Hussien Aly, Samah Mohammed Ahmed Abdellatif, Nada Ayman Gad, Sara Mostafa Makkeyah conducting the study, collecting the data.
Naglaa Mohammed Shaheen supervise the study.
Ahmed Mahmoud Okba perform the radiological section.
All authors reviewed the manuscript and agree for publication.
Funding
Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). The authors do not have any financial support. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Data availability
No datasets were generated or analysed during the current study.
Declarations
Competing interests
The authors declare no competing interests.
Competing interest
The authors declare no competing interests.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Rees DC, Williams TN, Gladwin MT (2010) Sickle-cell disease. Lancet 376(9757):2018–2031 10.1016/S0140-6736(10)61029-X [DOI] [PubMed] [Google Scholar]
- 2.Gupta K, Jahagirdar O, Gupta K (2018) Targeting pain at its source in sickle cell disease. Am J Physiol Regul Integr Comp Physiol 315(1):R104–R112 10.1152/ajpregu.00021.2018 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Sundd P, Gladwin MT, Novelli EM (2019) Pathophysiology of Sickle Cell Disease. Annu Rev Pathol 24(14):263–292 10.1146/annurev-pathmechdis-012418-012838 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Osunkwo I, Manwani D, Kanter J (2020) Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease. Ther Adv Hematol 29(11):2040620720955000 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Sagi V, Mittal A, Tran H, Gupta K (2021) Pain in sickle cell disease: current and potential translational therapies. Transl Res 234:141–158. 10.1016/j.trsl.2021.03.007 [DOI] [PMC free article] [PubMed]
- 6.Cox SE, Hart E, Kirkham FJ, Stotesbury H (2020) L-Glutamine in sickle cell disease. Drugs Today (Barc) 56(4):257–268 10.1358/dot.2020.56.4.3110575 [DOI] [PubMed] [Google Scholar]
- 7.Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP, Investigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease (2018) A phase 3 trial of l-Glutamine in sickle cell disease. N Engl J Med 379(3):226–235. 10.1056/NEJMoa1715971 [DOI] [PubMed]
- 8.Food and Administration, Approval (2018) FDA approved l-glutamine powder for the treatment of sickle cell disease. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approved-l-glutamine-powder-treatment-sickle-cell-disease#:~:text=On%20July%207%2C%202017%2C%20the%20U.S.%20Food%20and,adult%20and%20pediatric%20patients%205%20years%20and%20older. Accessed 12 Jan 2024
- 9.Bender Ma and Carlberg K (2003) Sickle Cell Disease. Gene Reviews; Seattle (WA): University of Washington, Seattle; 1993. 2003 [PubMed]
- 10.Niihara Y, Macan H, Eckman JR, Koh H, Cooper ML, Ziegler T, Razon R, Tanaka K, Stark CW, Johnson CS (2014) L-Glutamine Therapy Reduces Hospitalization for Sickle Cell Anemia and Sickle β°-Thalassemia Patients at Six Months – A Phase II Randomized Trial. Clin Pharmacol Biopharm 3:116 10.4172/2167-065X.1000116 [DOI] [Google Scholar]
- 11.Sadaf A, Quinn CT (2020) L-glutamine for sickle cell disease: Knight or pawn? Exp Biol Med (Maywood) 245:146–154 10.1177/1535370219900637 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Panepinto JA, Torres S, Bendo CB, McCavit TL, Dinu B, Sherman-Bien S, Bemrich-Stolz C, Varni JW (2013) PedsQL™ sickle cell disease module: feasibility, reliability, and validity. Pediatr Blood Cancer 60(8):1338–1344 10.1002/pbc.24491 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Vichinsky E, Levine L, Bhatia S, Bojanowski J et al (2008) Endocrine dysfunctions in thalassemia. In Standards of care guidelines for thalassemia, Children’s Hospital and Research Center Oakland. Indian J Endocrinol Metab 17(1):8–18 [Google Scholar]
- 14.Arya AD, Sachdeva A, Yadav S, Khanna VK, Arya SC (2005) Hypogonadism in thalassemia major. Blood 106(11):3844. 10.1182/blood.V106.11.3844.3844
- 15.Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols FT, Bonds DR, Brambilla D (1998) Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 339(1):5–11 10.1056/NEJM199807023390102 [DOI] [PubMed] [Google Scholar]
- 16.Ebeid FSE (2023) The implementation of automated red blood cell exchange (erythrocytapheresis) as a treatment modality in sickle cell disease patients: Single center experience. Transfus Apher Sci 62(4):103719 10.1016/j.transci.2023.103719 [DOI] [PubMed] [Google Scholar]
- 17.Elalfy MS, Hamdy M, El-Beshlawy A, Ebeid FSE, Badr M, Kanter J, Inusa B, Adly AAM, Williams S, Kilinc Y, Lee D, Fradette C, Rozova A, Temin NT, Tricta F, Kwiatkowski JL (2023) Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years. Blood Adv 7(4):611–619 10.1182/bloodadvances.2021006778 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Chou ST, Flanagan JM, Vege S, Luban NLC, Brown RC, Ware RE, Westhoff CM (2017) Whole-exome sequencing for RH genotyping and alloimmunization risk in children with sickle cell anemia. Blood Adv 1(18):1414–1422 10.1182/bloodadvances.2017007898 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 332(20):1317–22 10.1056/NEJM199505183322001 [DOI] [PubMed] [Google Scholar]
- 20.Quinn CT (2018) l-Glutamine for sickle cell anemia: more questions than answers. Blood 132(7):689–693 10.1182/blood-2018-03-834440 [DOI] [PubMed] [Google Scholar]
- 21.Zerez CR, Lachant NA, Lee SJ, Tanaka KR (1988) Decreased erythrocyte nicotinamide adenine dinucleotide redox potential and abnormal pyridine nucleotide content in sickle cell disease. Blood 71(2):512–515 10.1182/blood.V71.2.512.512 [DOI] [PubMed] [Google Scholar]
- 22.Niihara Y, Zerez CR, Akiyama DS, Tanaka KR (1997) Increased red cell glutamine availability in sickle cell anemia: demonstration of increased active transport, affinity, and increased glutamate level in intact red cells. J Lab Clin Med 130(1):83–90 10.1016/S0022-2143(97)90062-7 [DOI] [PubMed] [Google Scholar]
- 23.Ballas SK, Lusardi M (2005) Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol 79:17–25 10.1002/ajh.20336 [DOI] [PubMed] [Google Scholar]
- 24.Panepinto JA, Brousseau DC, Hillery CA, Scott JP (2005) Variation in hospitalizations and hospital length of stay in children with vaso-occlusive crises in sickle cell disease. Pediatr Blood Cancer 44(2):182–186 10.1002/pbc.20180 [DOI] [PubMed] [Google Scholar]
- 25.Salman EK, Haymond MW, Bayne E, Sager BK, Wiisanen A, Pitel P, Darmaun D (1996) Protein and energy metabolism in prepubertal children with sickle cell anemia. Pediatr Res 40(1):34–40 10.1203/00006450-199607000-00007 [DOI] [PubMed] [Google Scholar]
- 26.Schafer FQ, Buettner GR (2001) Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 30(11):1191–1212 10.1016/S0891-5849(01)00480-4 [DOI] [PubMed] [Google Scholar]
- 27.Marc Rhoads J, Wu G (2009) Glutamine, arginine, and leucine signaling in the intestine. Amino Acids 37(1):111–122 [DOI] [PubMed]
- 28.Xue H, Sufit AJ, Wischmeyer PE (2011) Glutamine therapy improves outcome of in vitro and in vivo experimental colitis models. JPEN J Parenter Enteral Nutr 35(2):188–197 10.1177/0148607110381407 [DOI] [PubMed] [Google Scholar]
- 29.Liboni K, Li N, Neu J (2004) Mechanism of glutamine-mediated amelioration of lipopolysaccharide-induced IL-8 production in Caco-2 cells. Cytokine 26(2):57–65 10.1016/j.cyto.2003.12.008 [DOI] [PubMed] [Google Scholar]
- 30.Ware RE, de Montalembert M, Tshilolo L, Abboud MR (2017) Sickle cell disease. Lancet 390(10091):311–323 10.1016/S0140-6736(17)30193-9 [DOI] [PubMed] [Google Scholar]
- 31.Rigano P, De Franceschi L, Sainati L, Piga A, Piel FB, Cappellini MD, Fidone C, Masera N, Palazzi G, Gianesin B, Forni GL, Italian Multicenter Study of Hydroxyurea in Sickle Cell Anemia Investigators (2018) Real-life experience with hydroxyurea in sickle cell disease: a multicenter study in a cohort of patients with heterogeneous descent. Blood Cells Mol Dis 69:82–89. 10.1016/j.bcmd.2017.08.017 [DOI] [PubMed]
- 32.Elenga N, Loko G, Etienne-Julan M, Al-Okka R, Adel AM, Yassin MA (2022) Real-World data on efficacy of L-glutamine in preventing sickle cell disease-related complications in pediatric and adult patients. Front Med (Lausanne) 1(9):931925 10.3389/fmed.2022.931925 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.ElAlfy MS, Ebeid FSE, Kamal TM, Eissa DS, Ismail EAR, Mohamed SH (2019) Angiotensinogen M235T Gene Polymorphism is a Genetic Determinant of Cerebrovascular and Cardiopulmonary Morbidity in Adolescents with Sickle Cell Disease. J Stroke Cerebrovasc Dis 28(2):441–449 10.1016/j.jstrokecerebrovasdis.2018.10.019 [DOI] [PubMed] [Google Scholar]
- 34.Corvest V, Blais S, Dahmani B, De Tersant M, Etienney AC, Maroni A, Ormières C, Roussel A, Pondarré C (2018) Vasculopathie cérébrale de l’enfant drépanocytaire : points clés et nouveautés [Cerebral vasculopathy in children with sickle cell disease: Key issues and the latest data]. Arch Pediatr 25(1):63–71 10.1016/j.arcped.2017.11.015 [DOI] [PubMed] [Google Scholar]
- 35.Elalfy MS, Ibrahim AS, Ibrahim GS, Hussein HMAG, Mohammed HGE, Ebeid FSE (2021) Hidden brain iron content in sickle cell disease: impact on neurocognitive functions. Eur J Pediatr 180(8):2677–2686 10.1007/s00431-021-04189-7 [DOI] [PubMed] [Google Scholar]
- 36.Ogu UO, Badamosi NU, Camacho PE, Freire AX, Adams-Graves P (2021) Management of Sickle Cell Disease Complications Beyond Acute Chest Syndrome. J Blood Med 25(12):101–114 10.2147/JBM.S291394 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Weisman JK, Diamond CE, Kappa S, Nickel RS (2020) Transcranial Doppler Screening Adherence among Children with Sickle Cell Anemia Seen in the Emergency Department. J Pediatr 217:172-176.e1 10.1016/j.jpeds.2019.10.049 [DOI] [PubMed] [Google Scholar]
- 38.Cohen Kadosh K, Krause B, King AJ, Near J, Cohen KR (2015) Linking GABA and glutamate levels to cognitive skill acquisition during development. Hum Brain Mapp 36(11):4334–4345 10.1002/hbm.22921 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Stotesbury H, Kirkham FJ, Kölbel M, Balfour P, Clayden JD, Sahota S, Sakaria S, Saunders DE, Howard J, Kesse-Adu R, Inusa B, Pelidis M, Chakravorty S, Rees DC, Awogbade M, Wilkey O, Layton M, Clark CA, Kawadler JM (2018) White matter integrity and processing speed in sickle cell anemia. Neurology 90(23):e2042–e2050 10.1212/WNL.0000000000005644 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Sands S, Ladas EJ, Kelly KM, Weiner M, Lin M, Ndao DH, Dave A, Vahdat LT, Bender JG (2017) Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer. Support Care Cancer 25(3):701–708. 10.1007/s00520-016-3441-6 [DOI] [PMC free article] [PubMed]
- 41.Cruzat V, Macedo Rogero M, Noel Keane K, Curi R, Newsholme P (2018) Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation. Nutrients 10(11):1564 10.3390/nu10111564 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Jafri F, Seong G, Jang T, Cimpeanu E, Poplawska M, Dutta D, Lim SH (2022) L. glutamine for sickle cell disease: more than reducing redox. Ann Hematol 101(8):1645–1654 10.1007/s00277-022-04867-y [DOI] [PubMed] [Google Scholar]
- 43.Jegatheesan P, Beutheu S, Ventura G, Sarfati G, Nubret E, Kapel N, Waligora-Dupriet AJ, Bergheim I, Cynober L, De-Bandt JP (2016) Effect of specific amino acids on hepatic lipid metabolism in fructose-induced non-alcoholic fatty liver disease. Clin Nutr 35(1):175–182 10.1016/j.clnu.2015.01.021 [DOI] [PubMed] [Google Scholar]
- 44.Chamorro S, de Blas C, Grant G, Badiola I, Menoyo D, Carabaño R (2010) Effect of dietary supplementation with glutamine and a combination of glutamine-arginine on intestinal health in twenty-five-day-old weaned rabbits. J Anim Sci 88(1):170–180 10.2527/jas.2008-1698 [DOI] [PubMed] [Google Scholar]
- 45.Zhang Y, Lu T, Han L, Zhao L, Niu Y, Chen H (2017) L-Glutamine Supplementation Alleviates Constipation during Late Gestation of Mini Sows by Modifying the Microbiota Composition in Feces. Biomed Res Int 2017:4862861. 10.1155/2017/4862861 [DOI] [PMC free article] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
No datasets were generated or analysed during the current study.